

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**LISTING OF CLAIMS:**

**1-32. (cancelled)**

**33. (previously presented)** An isolated protein that comprises or is constituted by the amino acid sequence of SEQ ID NO: 1.

**34. (previously presented)** The isolated protein of claim 33, wherein said protein comprises or is constituted by the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3.

**35. (previously presented)** An isolated nucleotide sequence encoding the protein that comprises or is constituted by the amino acid sequence of SEQ ID NO: 1.

**36. (currently amended)** A recombinant vector comprising a nucleotide sequence encoding ~~the~~ an isolated protein ~~as defined in claim 33~~ wherein the isolated protein comprises or is constituted by the amino acid sequence of SEQ ID NO: 1.

**37. (previously presented)** The recombinant vector according to claim 36, wherein said recombinant vector is a plasmid, a cosmid, a phage, or a virus DNA.

**38. (currently amended)** The recombinant vector according to claim 36, further comprising operable elements for expression in a host cell of the isolated protein encoded by the nucleotide sequence, inserted into a said vector.

**39. (currently amended)** An isolated host cell transformed with a recombinant vector containing a nucleotide sequence encoding ~~the~~ an isolated protein ~~as defined in claim 36~~ wherein the isolated protein comprises or is constituted by the amino acid sequence of SEQ ID NO: 1.

**40. (previously presented)** The host cell according to claim 39, said host cell being chosen from bacteria, yeast, fungi, plant cells, or mammalian cells.

**41. (previously presented)** A pharmaceutical composition comprising, as active ingredient, the isolated protein according to claim 33, in combination with a pharmaceutically acceptable vehicle.

**42. (previously presented)** A pharmaceutical composition, comprising as active ingredient, a protein represented by the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3, in combination with a pharmaceutically acceptable vehicle.

**43. (currently amended)** The pharmaceutical composition according to claim 41, in which the isolated protein[[,]] is in combination with a ~~variant of the~~ paraoxonase protein comprising ~~the~~ an amino acid sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

**44. (currently amended)** The pharmaceutical composition according to claim 43, wherein the isolated protein is ~~the~~ an isolated protein of SEQ ID NO: 2 or SEQ ID NO: 3.

**45. (currently amended)** A combination product comprising:

at least the isolated protein according to claim 33, and

at least one ~~variant of the~~ paraoxonase protein consisting of the amino acid sequence selected from the group consisting of: SEQ ID NO: 4, ~~of~~ SEQ ID NO: 5, and SEQ ID NO: 6,

for simultaneous or separate use, or use spread over time, intended for the prophylaxis or treatment of intoxications caused by insecticides or nerve agents.

**46. (currently amended)** The combination product according to claim 45, wherein said isolated protein is ~~the~~ an isolated protein of SEQ ID NO: 2 or SEQ ID NO: 3.

**47. (previously presented)** The combination product according to claim 45, wherein said nerve agents are soman, VX, sarin, or tabun.

**48 - 54. (cancelled)**

**55. (new)** A method for determining the concentration in human plasma of the isolated protein according to claim 33, said method being chosen from:

- eletrophoretic methods;
- purification of the protein;
- quantification of protein activity; and
- immunoassay of the protein using polyclonal/monoclonal antibodies directed against said protein.

**56. (new)** The method for determining the concentration in human plasma of the isolated protein according to claim 55, wherein the immunoassay is an ELISA-type immunoassay.

**57. (new)** The method according to claim 55, wherein said isolated protein is the isolated protein of SEQ ID NO: 2 or SEQ ID NO: 3.